Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MET097 in obesity and overweight
NCT06857617Phase 2Completed
- Sponsor
- Metsera
- Start
- Apr 2024
- Primary completion
- Jan 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obesity comparing (Part C) MET097 with (Part C) Placebo (2 arms). Primary endpoint: Percent change from baseline in body weight at 12 weeks. Started Apr 2024; status: completed.
02
Drugs
PF-08653944
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06857617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06857617.